After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.
Chipotle, Wendy's on the bull side and gold stocks on the bear side.
Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.
TheStreet’s Chris Versace and Bob Lang said biotech companies like Celgene (CELG) are slowly but surely staging a quiet resurgence.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.